Cargando…
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the c...
Autores principales: | Qi, Ruoyao, Cao, Jiali, Wu, Yangtao, Lei, Xing, He, Jinhang, Zhang, Liang, Fu, Rao, Chen, Feng, Wang, Yingbin, Zhang, Tianying, Xia, Ningshao, Yuan, Quan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196021/ https://www.ncbi.nlm.nih.gov/pubmed/37213494 http://dx.doi.org/10.3389/fmicb.2023.1173061 |
Ejemplares similares
-
Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice
por: Chen, Yuanzhi, et al.
Publicado: (2021) -
A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys
por: Kang, Ciming, et al.
Publicado: (2017) -
Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
por: Li, Jun, et al.
Publicado: (2023) -
HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018) -
A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice
por: Liu, Liqin, et al.
Publicado: (2022)